Five things for pharma marketers to know: Friday, February 24, 2017

PBMs' use of "clawbacks" prompt lawsuits; Merck's experimental antiviral drug prevents infection; EMA recommends Novartis' lung-cancer combo drug

WebMD considers sale or merger

Drugmakers are becoming much more cautious with their budgets, WebMD executives said.

MAHF honors Abbate and Lazur, Future Famers

MAHF honors Abbate and Lazur, Future Famers

The Medical Advertising Hall of Fame recognized dozens of industry leaders and rising agency executives.

Deloitte taps Havas Lynx's Mickelberg as MD

Deloitte taps Havas Lynx's Mickelberg as MD

Dennis Urbaniak has also been named chief digital officer at Havas Lynx.

Orphan drugs face criticism on prices — and from patients

Orphan drugs face criticism on prices — and from patients

When discussing the nation's ability to stomach orphan drug costs, an analyst has called the price tag "the straw that breaks the camel's back."

Five things for pharma marketers to know: Thursday, February 23, 2017

Five things for pharma marketers to know: Thursday, February 23, 2017

Harvard Pilgrim signs pay-for-performance deals with Lilly and Amgen; new advocacy group wants lower drug prices; Zykadia gets priority review

Almost one-third of programmatic ads violate IAB guidelines, study finds

Almost one-third of programmatic ads violate IAB guidelines, study finds

The report identifies four major issues of the 28% that were found to abuse IAB's standards.

Five things for pharma marketers to know: Wednesday, February 22, 2017

Five things for pharma marketers to know: Wednesday, February 22, 2017

Audit says MD Anderson Cancer Center mismanaged Watson partnership; Icahn takes stake in BMS; Sarepta sells priority review voucher to Gilead

Read the complete January 2017 digital edition

Read the complete January 2017 digital edition

Here you'll find everything you need to know from MM&M's January 2017 issue, including our health-tech preview, a deep dive into data science, and report on digital innovation from Japanese drugmakers.

Five things for pharma marketers to know: Tuesday, February 21, 2017

Five things for pharma marketers to know: Tuesday, February 21, 2017

Pharma industry remains focused on Alzheimer's, despite setbacks; few new diabetes drugs in development; the FDA issues complete response letter to Trevena

How VAYA Pharma used Facebook ads for its ADHD campaign

How VAYA Pharma used Facebook ads for its ADHD campaign

The campaign would require a two-fold approach: Facebook link ads and Facebook Audience Network.

Five things for pharma marketers to know: Friday, February 17, 2017

Five things for pharma marketers to know: Friday, February 17, 2017

Microsoft reenters healthcare market; Trump accuses Cummings of avoiding drug-pricing meeting; Trump says ACA replacement plan to be unveiled in March

Roche gears up to enter loaded hemophilia A drug market

Roche gears up to enter loaded hemophilia A drug market

A loaded hemophilia A drug market is an indication patients in and around it are well-served, but that hasn't stopped contenders such as Roche's emicizumab.

Five things for pharma marketers to know: Thursday, February 16, 2017

Five things for pharma marketers to know: Thursday, February 16, 2017

The FDA approves Valeant's psoriasis drug; PhRMA to review its membership criteria; Lions Health announces pharma and health and wellness jury presidents

Industry hires and promotions: February 2017

Industry hires and promotions: February 2017

Novo Nordisk appoints new CEO, and more people moves for you to know about

Five things for pharma marketers to know: Wednesday, February 15, 2017

Five things for pharma marketers to know: Wednesday, February 15, 2017

Pharma execs raise concerns about Trump's plans for the FDA; Merck ends study of experimental Alzheimer's drug; Amgen seeks new indication for Blincyto

Top 25 rare disease brands, by sales

Top 25 rare disease brands, by sales

Teva Pharmaceutical Industries' Copaxone is by far the top-selling drug, bringing in $3.2 billion in U.S. sales in 2015.

On drug pricing, Acorda CEO is optimistic

On drug pricing, Acorda CEO is optimistic

Acorda CEO Ron Cohen applauded Marathon's move to pause the commercial activities for its new DMD drug.

Five things for pharma marketers to know: Tuesday, February 14, 2017

Five things for pharma marketers to know: Tuesday, February 14, 2017

More older Americans are taking at least three psychiatric drugs; Marathon to pause launch of Emflaza; Aetna and Humana call off deal

Bayer creates 'everyday hero' campaign for aspirin

Bayer creates 'everyday hero' campaign for aspirin

The drugmaker worked with creative agency BBDO and PR firm Marina Maher Communications to develop the campaign.

Agency Spotlight

Featured Listings

LevLane

LevLane

Featured Work: Kennedy Health brings sophisticated healthcare to South Jersey, and we wanted this ...

OPINION

Newsletters